Table 6 Most common adverse reactions
n (%) | PLD group (N = 362) | Epirubicin group (N = 851) |
|---|---|---|
Myelosuppression | 19 (5.3%) | 72 (8.5%) |
Decreased appetite | 8 (2.2%) | 37(4.4%) |
Cardiotoxicity | 8 (2.2%) | 56 (6.6%) |
Gastrointestinal reaction | 8 (2.2%) | 31 (3.6%) |
Alopecia | 5 (1.4%) | 29 (3.4%) |
Nausea | 21 (5.8%) | 17 (2.0%) |
D-dimer increase | 0 (0.0%) | 8 (0.9%) |
Transaminase increase | 0 (0.0%) | 7 (0.8%) |
Dizziness | 1 (0.3%) | 6 (0.7%) |
Vomiting | 0 (0.0%) | 8 (0.9%) |
Abnormal liver function | 0 (0.0%) | 4 (0.5%) |